Is Exact Sciences Corporation (EXAS) a Buy, Sell, or Hold?
Exact Sciences Corporation
NASDAQ:EXAS
$104.91 USD
$0 (0.0%)
- Volume
- 21.56M
- Average Volume
- 2.53M
- Market Capitalization
- $20.03B
- P/E Ratio
- -95.69
- Dividend Yield
- 0.00%
- Price Target
- $105.00
- Year High
- $104.98
- Year Low
- $38.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.23
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Kevin T. Conroy |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | EXAS |
| CUSIP | 30063P105 |
| CIK | 0001124140 |
| Web | https://www.exactsciences.com |
| Phone | 608 284 5700 |
| Currency | USD |
| Employees | 6900 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.23 |
| Quick Ratio | 1.97 |
| Cash Ratio | 1.49 |
Sales & Book Value
| Annual Sales | $3.25B |
| Price / Sales | 6.17 |
| Cash Flow | 1.88 |
| Price / Cash Flow | 56.13 |
| Price / Book | 8.29 |
Price Target and Rating
| Average Stock Price Forecast | $105.00 |
| High Stock Price Forecast | $105.00 |
| Low Stock Price Forecast | $105.00 |
| Forecast Upside/Downside | -0.09% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.1 |
| Trailing P/E Ratio | -95.69 |
| PEG Ratio | -1.09 |
| P/E Growth | -1.09 |
| Net Income | $-207.95M |
| Net Margin | -6.40% |
| Pretax Margin | -6.28% |
| Return on Equity | -8.51% |
| Return on Assets | -3.55% |
Financials Score
| AltmanZ Score | 2.97 |
| Piotroski Score | 5.00 |
| Working Capital | 788.41M |
| Total Assets | 5.86B |
| Ebit | -167.24M |
| Market Cap | 20.03B |
| Total Liabilities | 3.46B |
Poll Results
About Exact Sciences Corporation (NASDAQ:EXAS) Stock
Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy de ... signed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering
2026-07-03 16:00:00
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
2026-04-16 10:51:58
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.
Frequently Asked Questions
-
What is the current Exact Sciences Corporation (EXAS) stock price?
-
Exact Sciences Corporation(NASDAQ:EXAS) stock price is $104.91 in the last trading session. During the trading session, EXAS stock reached the peak price of $104.98 while $38.81 was the lowest point it dropped to. The percentage change in EXAS stock occurred in the recent session was 0.0% while the dollar amount for the price change in EXAS stock was $0.
-
EXAS's industry and sector of operation?
-
The NASDAQ listed EXAS is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of EXAS?
-
Graham Lidgard | Emeritus Chief Science Officer
James Herriott | Senior Vice President, General Counsel & Secretary
Nassar Nizami | Chief Information Officer
Derek Leckow | Vice President of Investor Relations
Aaron Bloomer | EVP & CFO -
How many employees does EXAS have?
-
Number of EXAS employees currently stands at 6900. EXAS operates from 5505 Endeavor Lane, Madison, WI 53719, US.
-
Link for EXAS official website?
-
Official Website of EXAS is: https://www.exactsciences.com
-
How do I contact EXAS?
-
EXAS could be contacted at phone #608 284 5700 and can also be accessed through its website. EXAS operates from 5505 Endeavor Lane, Madison, WI 53719, US.
-
How many shares of EXAS are traded daily?
-
The average number of EXAS shares traded daily for last 3 months was 2.53M.
-
What is the market cap of EXAS currently?
-
The market value of EXAS currently stands at $20.03B with its latest stock price at $104.91